Natural killer (NK) cells are essential in the elimination of virusinfected or transformed cells 1 . Although beneficial in host protection against infectious disease and cancer, irradiation-resistant mouse NK cells can reject bone marrow cell grafts [2] [3] [4] [5] . This process whereby NK cells in F 1 recipients reject parental bone marrow grafts has been called 'F 1 hybrid resistance' 6, 7 . Initially, the hypothesis proposed to explain hybrid resistance was that there is expression of hybrid histocompatibility antigens on parental bone marrow cells that are not expressed in the F 1 hybrid mice. Genetic mapping studies have suggested that in at least some mouse strains, the genes regulating the hybrid histocompatibility antigens localize to the H-2S-H-2D region 8 . The ability of NK cells to recognize and reject parental bone marrow cells has been explained in part by the lack of inhibitory Ly49 receptors specific for parental H-2 proteins on a subset of NK cells in the F 1 recipient [9] [10] [11] [12] . Thus, a subset of NK cells in the F 1 recipient lacking inhibitory receptors for the parental bone marrow cells might eliminate these parental bone marrow grafts. However, the NK cell receptors that initiate the attack against bone marrow grafts have not been defined.
NKG2D is an activating receptor expressed on the cell surface of NK cells, activated CD8 + T cells and gd T cell receptor-positive T cells 13 . In resting NK cells, NKG2D associates with the DAP10 adaptor protein, and in activated mouse NK cells, an NKG2D isoform generated by alternative splicing can also associate with the DAP12 adaptor protein 14 . NKG2D binds to a family of ligands with structural homology to major histocompatibility complex (MHC) class I proteins 1, 15 . In mice, the retinoic acid early inducible 1 (Rae-1) family of proteins and H60 and MULT1 function as high-affinity ligands for NKG2D [16] [17] [18] . The genes encoding the Rae-1 proteins were first discovered by their expression in embryonic tissues 19, 20 ; they are mostly silent in normal, healthy tissues in adult mice but are induced by viral infection or cellular transformation. Here we have examined expression of the NKG2D ligands in bone marrow cells repopulating irradiated mice and have evaluated the function of NKG2D in hybrid resistance.
RESULTS

Expression of NKG2D ligands on mouse bone marrow cells
In BALB/c mice, Raet1a, Raet1b and Raet1c encode Rae-1a, Rae-1b and Rae-1g, respectively, whereas in C57BL/6 mice, Raet1d and Rae1e encode Rae-1d and Rae-1e, respectively 21 . Whether Raet1d and Rae1e in C57BL/6 mice represent distinct Raet1 loci or are allelic variants of Raet1a, Raet1b and Raet1c has not been determined because the genomic organization of the Raet1 genetic complex has not been established in these mouse strains. BALB/c but not C57BL/6 mice express functional H60 proteins 22 . To determine whether NKG2D ligands are expressed on bone marrow cells, we analyzed bone marrow cells isolated from BALB/c mice, C57BL/6 mice and (BALB/c Â C57BL/6) F 1 mice (called 'CB6F1 mice' here). We stained cells with a fusion protein of mouse NKG2D and immunoglobulin G (IgG) Fc and analyzed them by flow cytometry. We detected low expression of NKG2D ligands on freshly isolated BALB/c but not C57BL/6 bone marrow cells (Fig. 1a) . To determine which NKG2D ligands were expressed, we stained the bone marrow cells with monoclonal antibody (mAb) to all Rae-1 proteins, mAb to H60 and mAb to MULT1. Rae-1 and H60 had low expression on freshly isolated BALB/c bone marrow cells, whereas MULT1 was not detected (Fig. 1b) . In contrast, Rae-1 was not detected on freshly isolated splenocytes from BALB/c, C57BL/6 or CB6F1 mice (unpublished observation).
NK cells in F 1 recipients are able to reject parental bone marrow grafts [2] [3] [4] [5] . Therefore, we determined whether the BALB/c bone marrow cells that repopulated the spleen in an irradiated CB6F1 recipient expressed NKG2D ligands. To prevent rejection of the transplanted BALB/c bone marrow cells, we pretreated the recipient CB6F1 mice with antibody to NK1.1 (anti-NK1.1) to deplete the recipient of NK cells. As a control, we reconstituted a group of irradiated CB6F1 mice with syngeneic CB6F1 bone marrow cells. We isolated the hematopoietic cells repopulating the spleens of the CB6F1 mice 7 d after grafting and analyzed their expression of NKG2D ligands. We detected NKG2D ligands on the repopulating hematopoietic cells isolated from the spleens of CB6F1 recipients of BALB/c bone marrow but not those of CB6F1 recipients of CB6F1 bone marrow (Fig. 1c) . The BALB/c hematopoietic cells reconstituting the spleens of the irradiated CB6F1 recipients expressed mainly Rae-1, not H60 or MULT1 (Fig. 1d) .
To identify the population of hematopoietic cells that expressed Rae-1, we stained cells isolated from the spleens of CB6F1 recipients of CB6F1 bone marrow and CB6F1 recipients of BALB/c bone marrow with mAbs to hematopoietic lineage markers. At day 7 after transplantation, we detected Rae-1 on most cells isolated from the spleens of CB6F1 recipients of BALB/c bone marrow; however, we did not detect Rae-1 on a substantial proportion of cells from CB6F1 recipients of CB6F1 bone marrow. Essentially all Rae-1 + cells isolated from the CB6F1 recipients of BALB/c bone marrow expressed CD43 (Fig. 1e) . Rae-1 was also present on most cells expressing the granulocyte-associated Ly6C-G (Gr-1) protein and the myeloid cellassociated marker CD11b (Mac-1). Only a minor fraction of cells positive for the B cell-associated marker B220 or the erythrocyteassociated marker Ter119 expressed Rae-1, and we did not detect Rae-1 on CD3 + T cells (data not shown). We detected Rae-1 on a small subset of cells expressing the hematopoietic stem cell (HSC) markers c-Kit and Sca-1, although most Rae-1 + cells did not have these markers (Fig. 1f) . We evaluated the proliferation status of cells expressing Rae-1 in the CB6F1 recipients of BALB/c bone marrow by injecting bromodeoxyuridine into these mice 2 h and 12 h before collecting the spleen cells on day 7 after transplantation. Rae-1 was readily detected on a large fraction (but not all) of the proliferating progenitor cells in the spleen of the transplant recipients (Fig. 1g) .
In initial experiments, we isolated whole bone marrow from BALB/c donors and transplanted it into CB6F1 mice. To address whether Rae-1 is expressed on the progeny of HSCs, we treated donor BALB/c mice with 5-fluorouracil before collecting bone marrow to enrich it for HSCs; we then transplanted bone marrow from 5-fluorouraciltreated donors into CB6F1 recipients that had been pretreated with mAb to NK1.1 to deplete them of resident host NK cells. The bone (Fig. 1h) . A small population of Rae-1 + cells had low expression of c-Kit and Sca-1, although most Rae-1 + cells lacked both of these markers (data not shown). These results indicated that most proliferating BALB/c myeloid progenitor cells in the NK cell-depleted CB6F1 recipients expressed Rae-1.
NKG2D is involved in hybrid resistance
The expression of Rae-1 on the proliferating progenitor cells in the spleens of CB6F1 mice reconstituted with BALB/c bone marrow prompted us to determine whether NKG2D is involved in hybrid resistance. Thus, we transferred BALB/c bone marrow cells into irradiated CB6F1 mice pretreated with a control antibody, a neutralizing, nondepleting mAb to NKG2D (CX5) 23 (Fig. 2a) . The nondepleting, neutralizing mAb to NKG2D also increased incorporation of [ 125 I]UdR, comparable to the effects of depleting mice of NK cells.
We confirmed the ability of treatment with mAb to NKG2D to prevent rejection of BALB/c bone marrow cells by examining the cells repopulating the spleens on day 8 after transplantation. We detected Rae-1 + cells, mainly coexpressing CD43, Ly6C-G and CD11b, in the spleens of CB6F1 mice treated with mAb to NKG2D (Fig. 2b) ; however, we recovered many fewer cells from the mice treated with control antibody, and very few of those cells expressed Rae-1 (Fig. 2b) .
These data indicated that rejection of Rae-1 + BALB/c bone marrow cells in CB6F1 mice is efficiently prevented by the depletion of NK cells or by blocking the NKG2D receptor.
In CB6F1 recipient rejection of parental BALB/c bone marrow, the F 1 recipient mice express both H-2 d and H-2 b , while the donor bone marrow cells express only H-2 d . We sought to determine whether reactivity to H-2 d on the parental donor cells was necessary for NKG2D-dependent graft rejection. To address this, we transplanted BALB.B (H-2 b ) bone marrow into C57BL/6 (H-2 b ) recipients. The C57BL/6 recipients rejected BALB.B bone marrow; however, graft rejection was prevented either by blocking NKG2D or by depletion of recipients of NK cells ( Supplementary Fig. 2 online) . Therefore, NKG2D-dependent rejection of bone marrow does not require incompatibility in donor versus recipient MHC.
Genetic control of NKG2D ligand expression
Because C57BL/6 bone marrow cells, unlike BALB/c cells, had little or no expression of NKG2D ligands (Fig. 1a) , we investigated the function of NKG2D in hybrid resistance in CB6F1 mice against C57BL/6 parental bone marrow grafts. CB6F1 mice rejected C57BL/6 bone marrow cells, and this was prevented by depletion of NK cells in the recipient by treatment with the depleting mAb to NK1.1 (Fig. 3) . However, mAb to NKG2D had no effect on rejection of C57BL/6 parental bone marrow in the CB6F1 recipients, in contrast to the ability of mAb to NKG2D to allow engraftment of BALB/c parental Mice were treated as described in a, and splenocytes were collected on day 8 after transplantation. Cells were stained and data are presented as described in Figure 1e . Results were reproducible (at least two independent experiments) and representative data are presented.
bone marrow in these recipients (Fig. 2a) . These results indicate that both NKG2D-dependent and NKG2D-independent mechanisms are operative in NK cell-mediated bone marrow rejection and that these are genetically regulated. Differential expression of the NKG2D ligands by bone marrow cells in different mouse stains may be an important consideration in transplantation and may influence whether NKG2D is involved in NK cell-mediated rejection. We detected NKG2D ligands on freshly isolated bone marrow cells from BALB/c but not C57BL/6 mice ( Fig. 1) . Consistent with the finding that Rae-1 was expressed on proliferating BALB/c bone marrow progenitor cells in vivo (Fig. 1g) , Rae-1 expression was upregulated by culture of BALB/c bone marrow in vitro with interleukin 3 (IL-3), stem cell factor and IL-6 ( Table 1) . Therefore, we assessed the expression of Rae-1, H60 and MULT1 on in vitro-cultured bone marrow cells from several different mouse strains (including C57BL/6, BALB/c, BALB.B, C3H, CBA, CBA/J, DBA/2, FVB and NK1.1 congenic nonobese diabetic mice). We determined the percentages of in vitro cultured bone marrow cells expressing the NKG2D ligands and the amounts of ligand present on the cell surface ( Table 1) . BALB/c and BALB.B mice had the highest frequency of cells expressing NKG2D ligands and the highest expression of Rae-1, C57BL/6 mice had the lowest frequency of NKG2D ligand-bearing bone marrow cells, and other strains were similar to C57BL/6 or were intermediate between those strains. These results suggest that the NKG2D ligands are genetically regulated and may influence transplantation differently in different donorrecipient combinations.
NK cells reject Rae-1-transgenic bone marrow cells To evaluate whether expression of Rae-1 on C57BL/6 or CB6F1 bone marrow cells would cause rejection of syngeneic bone marrow grafts, we generated transgenic mice expressing a Rae-1e transgene driven by a promoter of the gene encoding human b-actin, which would result in Rae-1e expression in all tissues. We assessed the expression of Rae1e on freshly isolated bone marrow cells from C57BL/6 Rae-1e-transgenic mice (Fig. 4a) , which was similar to the expression of Rae-1 on the repopulating BALB/c bone marrow cells (Fig. 1d,e) .
We tested freshly isolated bone marrow cells from the Rae-1e-transgenic C57BL/6 mice as targets for IL-2-activated syngeneic, nontransgenic NK cells in a standard in vitro cytotoxicity assay. Activated NK cells killed freshly isolated Rae-1e-transgenic C57BL/6 bone marrow cells but not Rae-1e nontransgenic C57BL/6 bone marrow cells (Fig. 4b) . Cytotoxicity was blocked by mAb to NKG2D, demonstrating that the killing was NKG2D dependent. In accordance with the in vitro results, irradiated nontransgenic C57BL/6 mice rejected bone marrow cells from Rae-1e-transgenic C57BL/6 donors; rejection was prevented in mice treated with the neutralizing mAb to NKG2D but not those treated with control immunoglobulin (Fig. 4c) . We obtained similar results when we crossed the Rae-1e-transgenic C57BL/6 mice with BALB/c mice and grafted Rae-1e-transgenic CB6F1 bone marrow into nontransgenic CB6F1 recipients (data not shown). The Rae-1e-transgenic CB6F1 bone marrow cells, unlike nontransgenic CB6F1 bone marrow cells (Fig. 1c,e) , had high expression of Rae-1e and were rejected by the syngeneic nontransgenic CB6F1 recipients (data not shown). Rejection was prevented by the administration of the neutralizing, nondepleting mAb to NKG2D or by depletion of NK cells with mAb to NK1.1 (data not shown). Collectively, these findings demonstrate that C57BL/6 and CB6F1 NK cells can reject 'H-2-identical' bone marrow cells, if the cells express Rae-1. (a) Rae-1 expression in bone marrow. Freshly isolated bone marrow from wild-type C57BL/6 mice (C57BL/6 BM) and Rae-1e-transgenic C57BL/6 mice (Rae-1e Tg BM) was stained with control antibody (cIg) or mAb to all Rae-1 proteins (aRae-1). Data are presented as described in Figure 1b .
(b) Cytotoxicity assay. Freshly isolated bone marrow cells from wild-type C57BL/6 and Rae-1e-transgenic C57BL/6 mice were used as targets in a standard in vitro cytotoxicity assay with IL-2-activated wild-type NK cells as effectors in the presence of control antibody or mAb to NKG2D (clone 191004). mAbs, 10 mg/ml. E:T, effector/target ratio. (c) Bone marrow rejection. Rae-1e-transgenic and wild-type C57BL/6 bone marrow cells (4 Â 10 6 ) were transferred into irradiated C57BL/6 recipients, mice were injected with [ 125 I]UdR on day 5, and spleens were collected and radioactivity was measured on day 6. On day -2, mice were treated with a control antibody, mAb to NKG2D or mAb to NK1.1 (200 mg/mouse). 
DAP10 and DAP12 in NKG2D-mediated bone marrow rejection
In mice, alternative RNA splicing of NKG2D transcripts generates two protein isoforms called NKG2D-S and NKG2D-L. NKG2D-L is expressed mainly in resting NK cells and associates with the DAP10 adapter protein, whereas NKG2D-S is induced by activation of NK cells and associates with either DAP10 or DAP12 (ref. 14). To determine whether DAP10 or DAP12 or both are involved in NKG2D-mediated rejection, we transplanted bone marrow cells from Rae-1e-transgenic C57BL/6 mice into irradiated wild-type, DAP10-deficient and DAP12-deficient C57BL/6 recipients. We injected mice with [ 125 I]UdR on day 5 and collected spleens and measured the incorporation of radiolabel on day 6. Compared with wild-type C57BL/6 mice, DAP10-deficient C57BL/6 mice demonstrated impairment in their rejection of the Rae-1e-transgenic C57BL/6 bone marrow grafts (Fig. 5a) . In contrast, DAP12-deficient C57BL/6 recipients rejected the Rae-1e-transgenic C57BL/6 bone marrow more efficiently that DAP10-deficient C57BL/6 mice, although slightly less well than wild-type C57BL/6 mice (Fig. 5b) .
Wild-type, DAP10-deficient and DAP12-deficient C57BL/6 mice all failed to reject the Rae-1e-transgenic C57BL/6 bone marrow grafts when treated with the depleting mAb to NK1.1 or with the nondepleting, neutralizing mAb to NKG2D. These results indicate a predominant function for DAP10 and a lesser function for DAP12 in NKG2D-dependent bone marrow rejection.
Defective graft rejection in Rae-1e-transgenic mice In vitro activation of NK cells from nonobese diabetic mice induces expression of Rae-1, which results in ligand-dependent modulation of NKG2D on the NK cells 24 . Analysis of the expression of NKG2D on the surface of NK cells from the Rae-1e-transgenic C57BL/6 mice showed lower expression of NKG2D than that on NK cells from wild-type mice (Fig. 6a) . Although NKG2D was substantially diminished on NK cells in the Rae-1e-transgenic C57BL/6, the numbers of NK cells in the spleens and the expression of NK1.1, Ly49D, Ly49A, Ly49C-I, Ly49F-I-C-H and Ly49G2 on the NK cells were similar to those of wild-type NK cells (data not shown). To determine whether NKG2D function was impaired in Rae1e-transgenic NK cells, we did an antibody-redirected cytotoxicity assay using control antibody, mAb to NKG2D and mAb to NK1.1. Although the NK1.1-dependent cytotoxic activity of Rae-1e-transgenic NK cells was identical to that of wild-type C57BL/6 NK cells, NKG2D-dependent cytotoxicity was impaired in Rae-1e-transgenic NK cells (Fig. 6b) .
Because the Rae-1e transgene is driven by a promoter of a gene encoding b-actin in these transgenic mice, their NK cells express both ligand and receptor together. To determine whether wild-type (nontransgenic) NK cells were inactivated in vivo by constant exposure to NKG2D ligands, we generated bone marrow chimeras by transplanting wild-type Ly5.2 congenic C57BL/6 bone marrow into lethally irradiated Rae-1e-transgenic C57BL/6 (Ly5.1) recipients. At 3 months after transplantation, the number of NK cells in the spleens and the expression of NK1.1 (Fig. 6c) , Ly49D, Ly49A, Ly49C-I, Ly49F-I-C-H and Ly49G2 (data not shown) in Rae-1e-transgenic recipients of Ly5.2 bone marrow were similar to those in wild-type C57BL/6 recipients of Ly5.2 bone marrow. In contrast, NKG2D expression on NK cells was diminished in Rae-1e-transgenic recipients of Ly5.2 nontransgenic bone marrow (Fig. 6c) . Consistent with the diminished expression of NKG2D on the NK cells, NKG2D-dependent cytotoxic activity was impaired in Rae-1e-transgenic recipients of Ly5.2 nontransgenic bone marrow, as determined by an in vitro antibody-redirected cytotoxicity assay (Fig. 6d) . Furthermore, we investigated whether the chimeric Rae-1e-transgenic recipients of Ly5.2 nontransgenic bone marrow rejected the Rae-1e-transgenic C57BL/6 bone marrow cells. As expected, the NK cells that developed in the chimeric wild-type Ly5.1 C57BL/6 recipients of wild-type Ly5.2 C57BL/6 nontransgenic bone marrow efficiently rejected the transplanted Rae-1e-transgenic bone marrow cells (Fig. 6e) . In contrast, NK cells that developed in the chimeric Rae-1e-transgenic recipients of Ly5.2 C57BL/6 nontransgenic bone marrow failed to reject the transplanted Rae-1e-transgenic bone marrow cells (Fig. 6e) . These findings indicated that the NKG2D modulation of NK cells is caused by interaction with irradiationresistant recipient Rae-1 expressing cells in vivo and that this results in impairment of NKG2D function in vivo.
To investigate whether F 1 hybrid resistance is affected by the diminished expression of NKG2D on NK cells in the Rae-1e-transgenic C57BL/6 mice, we crossed the transgenic mice with BALB/c mice and tested the Rae-1e-transgenic CB6F1 mice for their ability to reject parental BALB/c bone marrow cells. Unlike wild-type CB6F1 mice, the Rae-1e-transgenic CB6F1 mice failed to reject BALB/c bone marrow cells (Fig. 6f) . Moreover, treatment with mAb to NK1.1 or mAb to NKG2D did not influence the [ 125 I]UdR incorporation of BALB/c bone marrow cells in the Rae-1e-transgenic CB6F1 recipients; however, depletion of NK cells or blocking NKG2D allowed engraftment of BALB/c bone marrow cells in wild-type CB6F1 recipients. These findings, together with the blocking experiments using mAb to NKG2D, indicate NKG2D is an important component of the F 1 hybrid resistance to BALB/c bone marrow grafts.
DISCUSSION
Here we have provided evidence that NKG2D is involved in hybrid resistance: the rejection of parental bone marrow grafts by F 1 recipients. Rae-1, an NKG2D ligand, is expressed on bone marrow cells in BALB/c mice and its expression is upregulated on progenitor cells Results were reproducible (in at least two independent experiments) and representative data are presented.
9 4 2 VOLUME 6 NUMBER 9 SEPTEMBER 2005 NATURE IMMUNOLOGY repopulating irradiated CB6F1 recipients. Rejection of parental BALB/c bone marrow cells by CB6F1 recipients was blocked by a neutralizing, nondepleting mAb to NKG2D. In contrast, repopulating C57BL/6 bone marrow cells express little NKG2D ligand, and rejection of parental C57BL/6 bone marrow by CB6F1 was NKG2D-independent, demonstrating the existence of both NKG2D-dependent and NKG2D-independent mechanisms of hybrid resistance. Furthermore, NK cells were able to reject syngeneic C57BL/6 bone marrow grafts when these otherwise normal bone marrow cells expressed sufficient NKG2D ligand. Therefore, in some situations, NKG2D ligand expression alone is sufficient to serve as a barrier for resistance to bone marrow transplantation. Several factors seem to regulate hybrid resistance. Activating and inhibiting Ly49 receptors for MHC class I have been proposed to influence NK cell-mediated bone marrow rejection; however, many of the experiments linking Ly49 to hybrid resistance have used mAbs that deplete NK cells expressing these receptors, rather than blocking specific receptor-ligand interactions 12, [25] [26] [27] . NK cells in wild-type mice can reject bone marrow grafts from syngeneic b 2 -microglobulin-null donors; therefore, in this case, NK cells apparently use an asyet-undefined, MHC class I-independent activating receptor for the detection and elimination of bone marrow cells 28 . Nonetheless, there is evidence that the activating Ly49D receptor expressed in C57BL/6 mice recognizes H-2 d (refs. 25,29,30 ) and in some cases this may contribute to hybrid resistance, although Ly49D apparently does not contribute to the rejection of parental bone marrow by CB6F1 recipients 27 .
The genetic regulation of the NKG2D ligands is also complex. C57BL/6 and BALB/c mice have different genes encoding the NKG2D ligands and they are regulated differently in the two strains. Here, BALB/c bone marrow cells had constitutively low expression of Rae-1 and these NKG2D ligands were upregulated during expansion of proliferating progenitor cell populations in irradiated recipients. In contrast, the Raet1 genes in C57BL/6 mice were more tightly regulated and demonstrated much lower expression on bone marrow cells. Notably, as in C57BL/6 mice, only low amounts of Rae-1 were expressed on CB6F1 bone marrow cells. Further studies are required to define the regulation of Raet genes in homozygous and heterozygous hosts. Additionally, our findings have demonstrated the existence of both NKG2D-dependent and NKG2D-independent mechanisms of hybrid resistance, with CB6F1 rejection of parental BALB/c bone marrow representing the former and parental C57BL/6 bone marrow representing the latter. It has been reported that CB6F1 mice reject C57BL/6 parental bone marrow cells more forcefully than BALB/c parental bone marrow grafts 31 , suggesting the possibility that NK cell-mediated rejection of BALB/c bone marrow may require costimulation by signals through the NKG2D receptor, whereas the as-yetunidentified mechanism of CB6F1 rejection of C57BL/6 parental bone marrow cells is sufficient without NKG2D activation. The complexity of hybrid resistance may be explained by the fact that different mouse strains express different activating and inhibitory Ly49 receptors, different H-2 ligands and different NKG2D ligands, which may be regulated in distinct ways depending on the genetic background. The Raet1 genes were identified first by their expression in mouse embryonic tissues 19 , but they are silent in most tissues in adult mice. Our study has indicated that expression of Rae-1 is upregulated on the BALB/c donor hematopoietic cells repopulating an irradiated host. Examination of the phenotype of the cells repopulating the spleens of the recipients indicated that the Rae-1-bearing cells were mainly myeloid lineage progenitors. We did not detect Rae-1 on bone marrow cells isolated from 5-fluorouracil-treated BALB/c mice, and in the reconstituted recipients, only a minor proportion of the Rae-1 + cells expressed Sca-1 and c-Kit, which are markers of HSCs. Furthermore, we did not detect Rae-1 expression on the population of freshly isolated bone marrow cells that contains HSCs (gating on lineage marker-negative, Thy-1-low, Sca1-high bone marrow cells; unpublished observation). Thus, it seems likely that Rae-1 is present mainly on the expanding progenitor cell populations, rather than the HSCs. It has also been suggested that HSCs are not direct targets of NK cellmediated rejection of bone marrow grafts 32 . In the early embryo, Rae-1 is expressed on cells in many tissues, including the brain, heart, limb buds and brachial arches 19 . Whether NKG2D ligands are expressed on the progeny of stem cells in tissues or organs other than hematopoietic cells remains to be determined and may have consequences for the transplantation of stem cells into immunocompetent adults.
METHODS
Mice. C57BL/6, BALB/c, CBA/JCr, FVB/NCr, C3H/HeJCr, DBA/2NCr and CB6F1 mice 6-8 weeks old were purchased from the National Cancer Institute Animal Program, and BALB.B mice were purchased from Jackson Laboratories. NK1.1-congenic nonobese diabetic mice were provided by A. Bendelac (University of Chicago, Chicago, Illinois). Rae-1e-transgenic mice were generated as described and were backcrossed onto the C57BL/6 background 33 . DAP12-deficient mice on the C57BL/6 background (backcrossed nine generations) have been described 34 , and DAP10-deficient mice were generated from C57BL/ 6 embryonic stem cells by standard methods (J.H.P., unpublished data). All experiments were done according to the guidelines of the University of California, San Francisco Committee on Animal Research (San Francisco, California) and the Schering Plough BioPharma Committee on Animal Research (Palo Alto, California).
Reagents, cytokines and antibodies. Mouse mAb to NKG2D, clone CX5 (rat IgG1 isotype), was generated as described 24 . Mouse mAb to NKG2D, clone 191004 (rat IgG2a isotype), was generated in a collaborative project with J.P. Houchins (R&D Systems). All mAbs to NKG2D recognize the NKG2D extracellular domain and efficiently block the binding of NKG2D to its ligands. For in vivo injection, we used the CX5 mAb to NKG2D and PK136 mAb to NK1.1 that did not contain detectable endotoxin (o0.3 pg/injection). The CX5 mAb to NKG2D is a blocking antibody that does not cause depletion of NKG2D-bearing NK cells or T cells when injected in vivo 23, 35, 36 (Supplementary Fig. 1 online) . Control rat IgG was purchased from Sigma. The mAb to all Rae-1 proteins (clone 186107, rat IgG2b isotype), mAb to H60 (clone 205310) and mAb to MULT1 (clone 237104) were generated in a collaborative project with J.P. Houchins (R&D Systems) 35, 36 . Other antibodies were purchased from BD PharMingen or eBiosocience. Mouse IL-3, stem cell factor and IL-6 were purchased from R&D Systems.
Bone marrow transplantation. The method for transplantation has been described 25 . Treatment with mAb (200 mg/mouse) was done 2 d before bone marrow transfer, and all recipients were treated with poly(I:C) (200 mg/mouse; Sigma) to 'boost' NK cell-mediated graft rejection 37 1 d before injection of bone marrow cells. On day 0, mice were irradiated by exposure to a lethal dose (11 Gy) of 137 Cs g-irradiation, and then 4 Â 10 5 or 4 Â 10 6 bone marrow cells were injected intravenously. At 5 d after transfer, the mice were given 26 mg of 5-fluoro-2¢-deoxyuridine (Sigma) intravenously to suppress endogenous thymidine synthesis 25 . Then, 30 min later, the mice were given 3 mCi [ 125 I]UdR (Amersham Life Science) intravenously. On day 6, spleens were removed from recipient mice and radioactivity was measured with a g-counter.
Generation of bone marrow chimeric mice. The method for this procedure has been described 38 . Ly5.2 C57BL/6 bone marrow cells (1 Â 10 7 ) were transferred intravenously into NK cell-depleted and irradiated recipient mice (absorbed dose of radiation, 11 Gy). During reconstitution, mice were maintained on antibiotics.
Preparation of NK cells. Samples were enriched for NK cells as described 39 . Spleen cells were incubated with mAb to CD4 (clone GK1.5) and mAb to CD8 (clone 53-6.7) and then these cells were mixed with magnetic beads coated with goat anti-mouse immunoglobulin and goat anti-rat immunoglobulin (Advanced Magnetic). Cells positive for CD4, CD8 and surface immunoglobulin were removed by magnetic cell sorting.
Flow cytometry. For detection of NKG2D ligands, we used the extracellular domain of mouse NKG2D fused to human IgG1 Fc (mNKG2D-Ig) 16 . A phycoerythrin-conjugated goat anti-human IgG Fcg fragment (Jackson ImmunoResearch) was used as a second-step reagent. Cells (1 Â 10 6 ) were stained with 0.5 mg of mNKG2D-Ig and with 0.25 mg of other lineage-specific mAbs. To determine which NKG2D ligands were expressed, cells were stained with biotinylated mAb to all five known Rae-1 proteins (Rae-1a, Rae-1b, Rae1g, Rae-1d and Rae-1e), to H60 or to MULT1. Phycoerythrin-conjugated streptavidin or allophycocyanin-conjugated streptavidin was used for detection of biotinylated mAbs. For detection of NKG2D, 1 Â 10 6 cells were stained with 0.25 mg biotinylated or phycoerythrin-labeled mAb to NKG2D (clone 191004). Cells were also stained with mAbs to CD43, Ly6C/G, CD11c, B220, CD3, Ter119, NK1.1 and CD49d (DX5). The cells were incubated with mAbs for 20 min and were washed with PBS containing 0.01% NaN 3 . Cells were analyzed with a FACSCalibur (Becton Dickinson). Viable lymphocyte populations were gated based on forward-and side-scatter profiles and by lack of propidium iodide staining.
Cytotoxicity assay. Monoclonal antibody-mediated redirected cytotoxicity assays were done as described 40 . For effector cells, C57BL/6 NK cells were cultured for 7 d in RPMI 1640 medium containing 10% FCS and 2,000 U/ml of recombinant human IL-2 (National Cancer Institute Biological Resources Branch Pre-clinical Repository). Target cells were labeled for 2 h at 37 1C with 50 mCi of Na 2 [ 51 Cr]O 4 in RPMI 1640 medium containing 10% FCS, were washed three times with medium and were used in cytotoxicity assays. 51 Cr-labeled target cells (5 Â 10 3 ) and effector cells were mixed in U-bottomed wells of a 96-well microtiter plate at various effector/target ratios in triplicate. After 4 h of incubation, cell-free supernatants were collected and radioactivity was measured with a Micro-beta counter (Wallac). The spontaneous release was less than 15% of the maximum release. The percentage of specific 51 Cr release was calculated according to the following formula: percent specific lysis ¼ (experimental release -spontaneous release) Â 100 / (maximal releasespontaneous release).
Note: Supplementary information is available on the Nature Immunology website.
